YBGJ Quote, Financials, Valuation and Earnings

Linike Medical Group has a net margin of -11740.4% compared to Yubo International Biotech's net margin of --. Yubo International Biotech's return on equity of -- beat Linike Medical Group's return on equity of --.

Yubo International Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand Linike Medical Group has an analysts' consensus of -- which suggests that it could grow by 36100.03%. Given that Linike Medical Group has higher upside potential than Yubo International Biotech, analysts believe Linike Medical Group is more attractive than Yubo International Biotech.

Yubo International Biotech has a beta of 3.022, which suggesting that the stock is 202.245% more volatile than S&P 500. In comparison Linike Medical Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Yubo International Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Linike Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech pays -- of its earnings as a dividend. Linike Medical Group pays out -- of its earnings as a dividend.

Yubo International Biotech quarterly revenues are $3.5K, which are larger than Linike Medical Group quarterly revenues of --. Yubo International Biotech's net income of -$580.8K is higher than Linike Medical Group's net income of --. Notably, Yubo International Biotech's price-to-earnings ratio is -- while Linike Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech is 8.41x versus -- for Linike Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis has a net margin of -11740.4% compared to Yubo International Biotech's net margin of 99.62%. Yubo International Biotech's return on equity of -- beat Nuwellis's return on equity of -918.02%.

Yubo International Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand Nuwellis has an analysts' consensus of $16.00 which suggests that it could grow by 1222.31%. Given that Nuwellis has higher upside potential than Yubo International Biotech, analysts believe Nuwellis is more attractive than Yubo International Biotech.

Yubo International Biotech has a beta of 3.022, which suggesting that the stock is 202.245% more volatile than S&P 500. In comparison Nuwellis has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.377%.

Yubo International Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Yubo International Biotech quarterly revenues are $3.5K, which are smaller than Nuwellis quarterly revenues of $2.4M. Yubo International Biotech's net income of -$580.8K is lower than Nuwellis's net income of $2.4M. Notably, Yubo International Biotech's price-to-earnings ratio is -- while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech is 8.41x versus 0.07x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -11740.4% compared to Yubo International Biotech's net margin of -23.59%. Yubo International Biotech's return on equity of -- beat Quanterix's return on equity of -10.38%.

Yubo International Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand Quanterix has an analysts' consensus of $21.00 which suggests that it could grow by 136.75%. Given that Quanterix has higher upside potential than Yubo International Biotech, analysts believe Quanterix is more attractive than Yubo International Biotech.

Yubo International Biotech has a beta of 3.022, which suggesting that the stock is 202.245% more volatile than S&P 500. In comparison Quanterix has a beta of 1.330, suggesting its more volatile than the S&P 500 by 33.045%.

Yubo International Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Yubo International Biotech quarterly revenues are $3.5K, which are smaller than Quanterix quarterly revenues of $35.4M. Yubo International Biotech's net income of -$580.8K is higher than Quanterix's net income of -$8.4M. Notably, Yubo International Biotech's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech is 8.41x versus 2.56x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging has a net margin of -11740.4% compared to Yubo International Biotech's net margin of -24.31%. Yubo International Biotech's return on equity of -- beat Varex Imaging's return on equity of -8.23%.

Yubo International Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand Varex Imaging has an analysts' consensus of -- which suggests that it could grow by 64.2%. Given that Varex Imaging has higher upside potential than Yubo International Biotech, analysts believe Varex Imaging is more attractive than Yubo International Biotech.

Yubo International Biotech has a beta of 3.022, which suggesting that the stock is 202.245% more volatile than S&P 500. In comparison Varex Imaging has a beta of 0.626, suggesting its less volatile than the S&P 500 by 37.362%.

Yubo International Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

Yubo International Biotech quarterly revenues are $3.5K, which are smaller than Varex Imaging quarterly revenues of $205.7M. Yubo International Biotech's net income of -$580.8K is higher than Varex Imaging's net income of -$50M. Notably, Yubo International Biotech's price-to-earnings ratio is -- while Varex Imaging's PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech is 8.41x versus 0.68x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.